Suchergebnisse - "Spiekermann, Karsten"

PubPharm (9)

1

Targeting FLT3 with a new-generation antibody-drug conjugate in combination with kinase inhibitors for treatment of AML

enthalten in: Blood | 2023

von Roas, M. | Vick, B. | Kasper, M. | +21

2

A series of novel aryl-methanone derivatives as inhibitors of FMS-like tyrosine kinase 3 (FLT3) in FLT3-ITD-positive acute myeloid leukemia

enthalten in: European journal of medicinal chemistry | 2020

von Sellmer, A. | Pilsl, B. | Beyer, M. | +13

3

The target landscape of clinical kinase drugs

enthalten in: Science (New York, N.Y.) | 2017

von Klaeger, S. | Heinzlmeir, S. | Wilhelm, M. | +45

CommentIn: Br J Cancer. 2018 Apr;118(7):936-937. - PMID 29545596

4

Loss of the histone methyltransferase EZH2 induces resistance to multiple drugs in acute myeloid leukemia

enthalten in: Nature medicine | 2017

von Göllner, S. | Oellerich, T. | Agrawal-Singh, S. | +25

5

Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib : results from the randomized CML-study IV

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2014

von Hehlmann, R. | Müller, M. | Lauseker, M. | +29

CommentIn: J Clin Oncol. 2014 Feb 10;32(5):471-4. - PMID 24297955

6

Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators : results from the randomized CML study IV

enthalten in: Annals of hematology | 2014

von Kalmanti, L. | Saussele, S. | Lauseker, M. | +25

7

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia

enthalten in: Blood | 2013

von Opatz, S. | Polzer, H. | Herold, T. | +20

8

Breakdown of the FLT3-ITD/STAT5 axis and synergistic apoptosis induction by the histone deacetylase inhibitor panobinostat and FLT3-specific inhibitors

enthalten in: Molecular cancer therapeutics | 2012

von Pietschmann, K. | Bolck, H. | Buchwald, M. | +7

9

KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival

enthalten in: Blood | 2006

von Schnittger, S. | Kohl, T. | Haferlach, T. | +4

1
[1]